Tradestie Institutional Equity Comparison Engine

OBIO vs ATYR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATYR Overall Edge

ATYR Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Growth & Margin, Momentum & Technical while OBIO counters with relative strength in Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus ATYR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OBIO N/M vs ATYR N/M Fwd P/E
Growth & Margin Winner ATYR
Op Margin -195.4% vs 0.0% ยท YoY -89.4% vs +0.0%
Momentum & Technical Winner ATYR
1Y +78.2% vs +541.4% ยท 52W Pos 89% vs 60%
Options & Structure Winner OBIO
BREAKOUT (<1st %ile IV) vs UNCLASSIFIED (36th %ile IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
1M Return +24.25%
1Y Return +78.17%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
ATYR NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
1M Return +2713.05%
1Y Return +541.43%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +78.17% ATYR +541.43% Spread: +463.26 pp (ATYR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue ATYR Revenue OBIO Op. Margin ATYR Op. Margin Margin Edge
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 N/A $10M N/A -152.2% ATYR
FY2022 $0M $10M -924.3% -446.8% ATYR
FY2023 $0M $0M -1866.2% -15557.8% OBIO
FY2024 $0M $0M -2437.5% -28899.6% OBIO
FY2025 $30M $0M -154.7% -40856.3% OBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (4) vs ATYR (4)
Institutional Metric OBIO ATYR Criterion Row Winner
Market Capitalization Scale $570.6M $15.6M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -89.4% +0.0% Higher Growth ATYR
Operating Margin (TTM) Profitability -195.4% 0.0% Higher Margin ATYR
Net Profit Margin Profitability -182.5% 0.0% Higher Margin ATYR
Return on Equity (ROE) Capital Efficiency -182.3% -93.7% Higher ROE ATYR
52-Week Range Position Momentum 89% ($3โ€“$7) 60% ($0โ€“$8) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.15ฮฒ ยท 80% Vol -9.57ฮฒ ยท 13806% Vol Lower Realized Risk OBIO
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite OBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs ATYR Buy Guide
OBIO BREAKOUT
33d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ATYR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor ATYR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.